New respiratory drugs neck and neck


Selection of inhalers

New combination therapies will compete for a share of the asthma and COPD treatment market © Shutterstock

A flurry of regulatory approvals has seen three new drugs approved for asthma and chronic obstructive pulmonary disease (COPD) in the European and Japanese markets.

Ultibro (indacaterol, glycopyrronium) from Novartis, has been approved for treating COPD in both the EU and Japan. Relvar (fluticasone furoate, vilanterol), developed by GlaxoSmithKline (GSK) and Theravance, has been approved for asthma treatment in Japan and recommended for approval in the EU for both asthma and COPD. It is already approved for COPD in the US, under the name Breo. Flutiform (fluticasone propionate, formoterol fumarate), from Skyepharma and Kyorin Pharmaceuticals, was approved in Japan for asthma treatment, having already been approved in Europe last year.

Both Relvar and Flutiform combine an airway-opening bronchodilator with an anti-inflammatory corticosteroid. Relvar is GSK’s successor to its blockbuster combination treatment Seretide (Advair in the US; fluticasone propionate, salmeterol xinafoate). ‘GSK has been researching and developing these molecules as a potential new combination treatment for over 10 years, and this opinion brings it one step closer to patients,’ said Patrick Vallance, GSK’s president of pharmaceuticals R&D, in a statement. Relvar still requires final marketing authorisation from the European commission.

While Seretide still enjoys market exclusivity, the US Food and Drugs Administration (FDA) has cleared the road for generic competitors. Earlier in September, the FDA issued guidance for generic companies as to what it will expect as proof that a generic version is equivalent to the complex combination therapy.

On the other hand, Novartis’s Ultibro represents a new class of combination treatments. It combines a conventional long-acting β2 adrenoreceptor agonist (LABA) bronchodilator with a long-acting muscarinic adrenoreceptor antagonist (LAMA), which also acts as a bronchodilator, but through a different receptor pathway. Both LABAs and LAMAs have previously been used on their own to treat COPD, but Ultibro is the first successful LABA–LAMA combination to reach the market. ‘We are very pleased that the European commission and Japan approved [Ultibro], nearly simultaneously, for COPD patients. This rapid approval in Japan reflects our build-up of clinical trial and regulatory capabilities in Japan,’ said David Epstein, division head at Novartis pharmaceuticals.

Both GSK (with Theravance) and AstraZeneca (after acquiring Pearl Therapeutics) have LAMA–LABA combination candidates in the pipeline.


Related Content

AstraZeneca stocks respiratory and cancer pipelines

31 July 2014 Business

news image

A $2bn deal with Almirall and a raft of acquisitions and partnership deals bulk up two focus areas for the company

Business roundup

28 March 2012 Business

news image

Industry news, April 2012

Most Read

Wind-powered lighting is almost a breeze

13 August 2014 Research

news image

Mechanoluminescent materials seen in a new light

Knock-out theory puts new spin on general anaesthesia

12 August 2014 Research

news image

Anaesthetics effect on proteins' electronic structure could explain mystery of how diverse molecules can cause unconsciousnes...

Most Commented

Why can we walk on custard?

12 July 2012 Research

news image

Scientists take a closer look at how shear-thickening fluids respond to impacts

Photon pinball identifies chemicals from afar

13 August 2014 Research

news image

Samples turned into random Raman lasers beam their secrets from over a kilometre away